Sign in
Taking people in United StatesNo phase

Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System

Key facts

Who runs it
Nyra Medical, Inc.
Where
Ann Arbor, Cincinnati, and Sacramento, United StatesSee the 3 sites
Trial code
Status
Recruiting
People taking part
30 people, planned
Started
2 Jul 2026
Expected to end
Dec 2032
Type of study
Interventional
Treatments tested
  • CARLEN System
Record updated
28 July 2026

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Age > 21 years at time of enrollment
  • Patient has provided informed consent, is willing and capable of participating in all testing, and agrees to return for all required post-procedure follow-up visits
  • Moderate-to-severe or severe (MR ≥ 3+) functional (secondary) mitral valve regurgitation
  • Symptomatic with mitral regurgitation (NYHA Class II, III, or ambulatory IV) despite maximally-tolerated guideline-directed medical therapy (GDMT) as determined by the local multidisciplinary Heart Team
  • Patient is suitable for transcatheter mitral valve repair as determined by the local multidisciplinary Heart Team and confirmed by the Eligibility Committee

Who cannot take part

  • Women who are pregnant, lactating, or planning to become pregnant during the clinical study. Women of child-bearing potential must have negative pregnancy test result within 2 weeks prior to the procedure
  • Known hypersensitivity or contraindications to necessary and routine medications including contrast compounds or components used in the CARLEN System that cannot be successfully pre-medicated, including nitinol, an alloy of nickel and titanium
  • Aortic valve disease requiring intervention or intervention
  • Severe pulmonary hypertension
  • Presence of significant congenital heart disease
  • Planned or scheduled cardiac surgery within next 12 months
  • Evidence of intracardiac mass, vegetation, or inflammatory or infectious valve disease
  • Left Ventricular Ejection Fraction (LVEF) < 20%
  • Estimated life expectancy of less than 12 months
  • Left ventricular end diastolic diameter (LVEDD) > 75 mm
  • Acute hemodynamic decompensation
  • Contraindicated for transesophageal echo (TEE)
  • Presence of other anatomical characteristics and/or significant comorbidities that in the judgement of the Investigator or Eligibility Committee precludes the subject from participation
  • Severe or greater tricuspid regurgitation
  • Severe right ventricular dysfunction
  • Endocarditis within last 90 days

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Jennifer Mischke, VP of Regulatory and ClinicalTaking people
  • The Christ HospitalCincinnati, United StatesContact: Jennifer Mischke, VP of Regulatory and ClinicalTaking people
  • University of California - DavisSacramento, United StatesContact: Jennifer Mischke, VP of Regulatory and ClinicalTaking people

About the trial

What the trial wants to find out

Safety and performance evaluation of the CARLEN System in patients with functional mitral valve regurgitation.

The group in the trial

  • CARLEN SystemTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ENHANCE EFS: Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System
Record updated
28 July 2026